Skip to main navigationSkip to main content
The University of Southampton
Cancer Research UK Centre

The TCR group was formed in 2006 in recognition of the need to support our continuing pursuit of scientific and clinical excellence in translational clinical research work within the Cancer Sciences Division, and following the award of full Experimental Cancer Medicine Centre (ECMC) status- a joint initiative between Cancer Research UK and the Departments of Health in England, Scotland, Wales and Northern Ireland. 

The group provides expertise to support the safe and efficient evaluation of novel cancer treatments being translated from the laboratory to the clinic, with emphasis on the careful and appropriate treatment of biological samples and data from clinical trials, covering the GMP Facility, Tissue Bank and various early phase Clinical Trials:

Investigator-led early phase Clinical Trials in Cancer Sciences Division

Other Translational Studies supported by ECMC

Activities of the TCR group include the development and formal validation of immunological endpoint assays, to provide the immunological tools for assessing the outcome of clinical testing. Assay development and validation is performed within a highly regulated framework and the TCR group aims to provide clear guidelines for quality assurance (QA Manager) and standards of Good Clinical Laboratory Practice in conducting these procedures.

The group additionally provides a point of contact for the Division for guidance on collection, storage and use of human tissue either from clinical studies or translational projects.

Our expertise in the development, optimisation and validation of endpoint assays for the measurement of novel biomarkers for clinical trials includes IFNγ ELISPOT/cultured ELISPOT (CD8+ and CD4+ T-cell responses to vaccine targets), ELISA development and validation for novel immunological strategies, such as anti-chimeric antibodies, PK assays), multiparameter analysis and phenotypic evaluation of cell populations by Flow Cytometry, and multiplex assays including the Luminex and Mesoscale Discovery platforms.

Contacts for further information:

Professor Christian Ottensmeier,
Dr. Tony Williams,

Assay Validation:

Dr Ann Mander,

Dr Ferdousi Chowdhury,

Dr. Angelica Cazaly,

Mrs. Lindsey Low,

Protein Expression:

Dr. Patrick Duries,

Quality Assurance Manager:

Dr Jason Partridge,

Tumour banking and GMP production:

Dr. Kathy Potter,

Cancer Research UK
Cancer Research UK
Privacy Settings